We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+13.33%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$90.2M
AUM Growth
-$6.75M
(-7%)
Cap. Flow
-$13.9M
Cap. Flow
% of AUM
-15.42%
Top 10 Holdings %
Top 10 Hldgs %
39%
Holding
124
New
12
Increased
17
Reduced
57
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$926K |
| 2 |
Pentair
PNR
|
+$778K |
| 3 |
CNSY
Cerenome
CNSY
|
+$606K |
| 4 |
Veritone
VERI
|
+$556K |
| 5 |
ZAGG
ZAGG Inc Common Stock (Delaware)
ZAGG
|
+$555K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$2.06M |
| 2 |
Tactile Systems Technology
TCMD
|
+$1.84M |
| 3 |
NeoGenomics
NEO
|
+$1.68M |
| 4 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$1.68M |
| 5 |
Ooma
OOMA
|
+$1.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.22% |
| 2 | Industrials | 11.67% |
| 3 | Technology | 10.9% |
| 4 | Financials | 3.3% |
| 5 | Communication Services | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axogen
AXGN
$2.77B
| $9.29M | 10.31% |
554,792
-37,375
| -6% | -$504K |
|
2
Abbott
ABT
$195B
| $4.02M | 4.46% |
82,710
-836
| -1% | -$37.8K |
|
3
Rockwell Medical
RMTI
$32.9M
| $3.49M | 3.87% |
4,001
-412
| -9% | -$338K |
|
4
AtriCure
ATRC
$2.47B
| $3.28M | 3.64% |
135,368
-1,849
| -1% | -$39.3K |
|
|
VYNT
5
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $3.27M | 3.63% |
5,522
-57
| -1% | -$33.3K |
|
|
6
NeoGenomics
NEO
$2.32B
| $2.77M | 3.07% |
308,800
-211,475
| -41% | -$1.68M |
|
7
LeMaitre Vascular
LMAT
$1.84B
| $2.66M | 2.95% |
85,250
-23,425
| -22% | -$676K |
|
8
Idexx Laboratories
IDXX
$43.7B
| $2.26M | 2.51% |
14,000
| – | – |
|
|
CSII
9
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.21M | 2.45% |
68,550
-67,500
| -50% | -$2.06M |
|
10
CryoPort
CYRX
$815M
| $1.91M | 2.11% |
387,481
-23,125
| -6% | -$75.4K |
|
11
Pfizer
PFE
$159B
| $1.75M | 1.94% |
55,002
-1,997
| -4% | -$63K |
|
12
Integer Holdings
ITGR
$4.26B
| $1.61M | 1.78% |
37,200
-1,350
| -4% | -$53.7K |
|
13
Eli Lilly
LLY
$1.05T
| $1.52M | 1.68% |
18,450
-1,750
| -9% | -$143K |
|
|
ZIXI
14
DELISTED
Zix Corporation
ZIXI
| $1.5M | 1.67% |
264,379
-16,510
| -6% | -$92.7K |
|
15
Microsoft
MSFT
$3.81T
| $1.49M | 1.65% |
21,585
-1,225
| -5% | -$84.1K |
|
16
Apyx Medical
APYX
$130M
| $1.48M | 1.64% |
599,817
-30,501
| -5% | -$75K |
|
17
AbbVie
ABBV
$451B
| $1.43M | 1.58% |
19,650
-25
| -0.1% | -$1.68K |
|
18
AT&T
T
$178B
| $1.22M | 1.35% |
42,781
+2,979
| +7% | +$87.8K |
|
19
Aflac
AFL
$58.4B
| $1.19M | 1.32% |
30,600
-1,000
| -3% | -$37.6K |
|
20
Altria Group
MO
$115B
| $1.17M | 1.3% |
15,700
-950
| -6% | -$69.5K |
|
|
ENTL
21
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $1.13M | 1.25% |
68,316
+8,299
| +14% | +$115K |
|
22
CVS Health
CVS
$119B
| $1.13M | 1.25% |
14,050
-933
| -6% | -$73.7K |
|
|
CGNT
23
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.12M | 1.25% |
645,303
-190,018
| -23% | -$326K |
|
24
JetBlue
JBLU
$1.81B
| $1.05M | 1.16% |
45,950
+2,200
| +5% | +$48.4K |
|
25
ANI Pharmaceuticals
ANIP
$1.67B
| $1.01M | 1.12% |
21,550
-600
| -3% | -$28.9K |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Perkins Capital Management held 124 positions worth $90.2M, down 7% from $96.9M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Perkins Capital Management withdrew a net $13.9M in Q2 2017, closing 18 positions and reducing 57 holdings. Its most notable exit was Tactile Systems Technology, an estimated $1.84M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 62% a quarter earlier, followed by Industrials and Technology.
Against the trend, Perkins Capital Management opened a new position in Cencora worth $983K.
- Perkins Capital Management's largest Q2 2017 buy was Cencora: 10,400 shares worth $983K.
- Perkins Capital Management added most to Cerenome in Q2 2017, an estimated $606K increase.
- Perkins Capital Management's biggest Q2 2017 reduction was Cardiovascular Systems, Inc., cutting an estimated $2.06M.
- Perkins Capital Management fully exited Tactile Systems Technology in Q2 2017, selling an estimated $1.84M.
- Perkins Capital Management's ten largest holdings make up 39% of its $90.2M portfolio in Q2 2017.
- Perkins Capital Management opened 12 new positions and closed 18 in Q2 2017.
- Perkins Capital Management's portfolio value fell 7% quarter-over-quarter to $90.2M.
Based on Perkins Capital Management's 13F filing for Q2 2017, filed 26 Jul 2017.